tiprankstipranks
ProKidney (PROK)
NASDAQ:PROK
US Market

ProKidney (PROK) AI Stock Analysis

Compare
132 Followers

Top Page

PR

ProKidney

(NASDAQ:PROK)

35Underperform
ProKidney's overall stock score is significantly impacted by its weak financial performance, marked by ongoing losses and negative equity, which are critical risks. The technical analysis suggests a bearish trend, further weighing on the score. Valuation metrics, particularly the negative P/E ratio, reflect the company's financial struggles. The lack of notable earnings call insights or corporate events results in a largely neutral impact from those factors.
Positive Factors
Market Potential
Rilparencel is a differentiated approach in diabetic CKD with blockbuster potential.
Regulatory Approval
FDA confirmed that PROACT 1 could be sufficient to support a BLA submission and full approval.
Negative Factors
Financial Performance
Topline results for the PROACT 1 study are expected in 3Q27, beyond the company's current cash runway.

ProKidney (PROK) vs. S&P 500 (SPY)

ProKidney Business Overview & Revenue Model

Company DescriptionProKidney (PROK) is a healthcare company specializing in the research and development of innovative treatments for chronic kidney disease (CKD). The company focuses on leveraging advanced biotechnological approaches to regenerate kidney function and improve patient outcomes. ProKidney operates within the biopharmaceutical sector and aims to provide cutting-edge therapies to address the unmet medical needs of CKD patients.
How the Company Makes MoneyProKidney makes money primarily through the development and commercialization of its proprietary therapies for chronic kidney disease. The company's revenue model centers on the successful progression of its treatments through clinical trials and obtaining regulatory approvals. Key revenue streams include potential licensing agreements, partnerships with other pharmaceutical companies, and eventual sales of approved therapies. Additionally, ProKidney may receive funding from grants, research collaborations, and investment from venture capital to support its research and development activities.

ProKidney Financial Statement Overview

Summary
ProKidney faces significant financial challenges, primarily due to ongoing losses and negative equity. The company has started to generate revenue, but profitability and operational efficiency remain major hurdles. Cash reserves provide some short-term relief, but improving revenue growth and managing costs are critical for long-term viability.
Income Statement
20
Very Negative
ProKidney's income statement reveals significant challenges. The company has experienced substantial net losses over multiple periods, with a negative net profit margin due to consistent negative net income. The gross profit margin is not applicable due to minimal or negative revenue in prior years, and the company has only recently started generating revenue. The EBIT and EBITDA margins are deeply negative, indicating operational inefficiencies and high costs relative to revenue.
Balance Sheet
15
Very Negative
The balance sheet shows a precarious position with negative stockholders' equity, indicating insolvency risk. The debt-to-equity ratio is not meaningful due to negative equity, and the equity ratio is also negative. Total liabilities are relatively low, but the high negative equity suggests financial instability. The company has a high cash balance, which provides some liquidity, but overall financial health appears weak.
Cash Flow
25
Negative
ProKidney's cash flow statement highlights substantial negative operating cash flow, indicating operational struggles. The free cash flow is also negative, exacerbating concerns about liquidity and sustainability. While there is some positive cash flow from financing activities, it is not sufficient to cover operational deficits in the long term. The company needs to improve cash generation from its core operations.
Breakdown
TTMDec 2023Dec 2022Dec 2021Dec 2020Dec 2019
Income StatementTotal Revenue
4.49M0.000.000.000.000.00
Gross Profit
1.67M-3.17M-3.04M-1.98M0.000.00
EBIT
-156.31M-151.52M-153.01M-55.11M-27.02M-19.16M
EBITDA
-132.02M-147.67M-143.99M-53.13M-26.02M-18.29M
Net Income Common Stockholders
-45.61M-35.47M-148.13M-55.15M-26.75M-79.61M
Balance SheetCash, Cash Equivalents and Short-Term Investments
362.95M362.95M490.25M20.56M4.58M15.23M
Total Assets
420.55M420.55M518.00M40.30M16.70M19.61M
Total Debt
4.41M4.41M2.40M1.33M1.56M1.01M
Net Debt
-56.24M-56.24M-487.85M-19.22M-3.02M-14.22M
Total Liabilities
29.22M29.22M13.06M13.38M6.84M3.72M
Stockholders Equity
-1.10B-1.10B-1.10B26.92M9.86M15.88M
Cash FlowFree Cash Flow
-129.14M-124.27M-78.94M-55.49M-30.64M-78.11K
Operating Cash Flow
-127.56M-90.07M-77.09M-50.30M-25.18M-76.81K
Investing Cash Flow
-90.51M-329.98M-1.74M-5.19M-5.46M-2.97K
Financing Cash Flow
134.77M-9.55M548.52M71.47M19.99M20.00K

ProKidney Technical Analysis

Technical Analysis Sentiment
Negative
Last Price1.04
Price Trends
50DMA
1.55
Negative
100DMA
1.69
Negative
200DMA
2.06
Negative
Market Momentum
MACD
-0.16
Positive
RSI
21.22
Positive
STOCH
10.47
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PROK, the sentiment is Negative. The current price of 1.04 is below the 20-day moving average (MA) of 1.35, below the 50-day MA of 1.55, and below the 200-day MA of 2.06, indicating a bearish trend. The MACD of -0.16 indicates Positive momentum. The RSI at 21.22 is Positive, neither overbought nor oversold. The STOCH value of 10.47 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PROK.

ProKidney Risk Analysis

ProKidney disclosed 94 risk factors in its most recent earnings report. ProKidney reported the most risks in the “Tech & Innovation” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

ProKidney Peers Comparison

Overall Rating
UnderperformOutperform
Sector (49)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
54
Neutral
$2.16B-37.08%80.76%53.98%
49
Neutral
$6.90B0.02-54.05%2.46%24.91%-3.14%
46
Neutral
$3.63B-19.20%-89.95%-123.71%
42
Neutral
$110.00M-54.21%-78.55%-0.92%
35
Underperform
$304.84M4.66%4.19%
32
Underperform
$875.43M-54.14%6.99%
27
Underperform
$22.84M-121.68%-5.32%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
PROK
ProKidney
0.99
-0.50
-33.56%
FATE
Fate Therapeutics
1.01
-6.63
-86.78%
RCKT
Rocket Pharmaceuticals
8.80
-19.36
-68.75%
CRSP
Crispr Therapeutics AG
43.49
-31.29
-41.84%
ALLK
Allakos
0.26
-1.14
-81.43%
MIRM
Mirum Pharmaceuticals
45.03
17.26
62.15%
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.